Identification of plasmid-encoded extended spectrum β-lactamases produced by a clinical strain of Proteus mirabilis

Pathologie Biologie

Volumn 57, Issue 3, 2009, Pages

  Mahrouki, S ^a   Ben Achour, N ^a   Chouchani, C ^a   Ben Moussa, M ^b   Belhadj, O ^a  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b MILITARY HOSPITAL OF TUNIS   (Tunisia)

Author keywords

Cefotaximase; Proteus mirabilis; Resistance; lactams

Indexed keywords

AMPICILLIN; AZTREONAM; CEFALOTIN; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; NALIDIXIC ACID; OXACILLIN; PENICILLIN G; STREPTOMYCIN; SULBACTAM; TETRACYCLINE; TICARCILLIN;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG IDENTIFICATION; DRUG SENSITIVITY; ENZYME MECHANISM; IC 50; INTENSIVE CARE UNIT; ISOELECTRIC POINT; NONHUMAN; PLASMID; PROTEUS MIRABILIS; TUNISIA;

EID: 64949105171     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2008.02.021     Document Type: Article

References (22)

1. Pagani L., Migliavacca R., Pallecchi L., Matti C., Giacobone E., Amicosante C., et al. Emerging extended-spectrum beta-lactamase in Proteus mirabilis. J Clin Microbiol 40 (2002) 1549-1552
2. Chanel C., Bonnet R., De champs C., Sirot D., Labia R., Sirot J., et al. Prevalence of β-lactamases among 1.072 Clinical Strains Proteus mirabilis: a 2-year survey in a French hospital. Antimicrob Agents Chemother 44 (2000) 1930-1935
3. Endimiani A., Luzzaro F., Brigante G., Perilli M., Lombardi G., Amicosante G., et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum β-Lactamases. Antimicrob Agents Chemother 49 (2005) 2598-2605
4. Jiunn-Jong Wu, Hung-Mo Chen, Wen-Chien Ko, Hsiu-Mei Wu, Shu-Huei Tsai, Jing-Jou Yan, et al. Prevalence of extended-spectrum (-lactamases in Proteus mirabilis in aTaiwanese university hospital, 1999 to 2005: identification of a novel CTX-M enzyme (CTX-M-66). Diagn Microbiol Infect Dis (2007)
5. Biendo M., Thomas D., Laurans G., Hamdad-Daoudi F., Canarelli B., Rousseau F., et al. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum β-lactamases in a French university hospital. Clin Microbiol Infect 11 (2005) 395-401
6. PL, Ho AY, Chow KH, Wong RC, Duan RS, Ho WL, Mak GC, Tsang KW, Yam WC, Yuen KY and al. Occurrence and molecular analysis of extendedspectrum β-lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002. J Antimicrob Chemother 2005; 55:840-845.
7. Kim J.Y., Park Y.J., Kim S.I., Kang M.W., Lee S.O., Lee K.Y., et al. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum β-lactamase VEB-1 in a Korean university hospital. J Antimicrob Chemother 54 (2004) 1144-1147
8. Ben Achour N., Chouchani C., Bouhawala N., Amor A., and Belhadj O. Clinical strain of Proteus mirabilis able to produce a plasmid mediated ceftazidimase. Pathol Biol (2007)
9. Hammami A., Arlet G., Ben Redjeb S., Grimont F., Ben Hassen A., Rekik A., et al. Nosocomial outbreak of acute gastroenteritis in a neonatal intensive care unit in Tunisia caused by multiply drug resistant Salmonella wien producing SHV-2- β-lactamase. Eur J Clin Microbiol Infect Dis 10 (1991) 641-646
10. Chouchani C., Berlemont R., Masmoudi A., Galleni M., Frere J.M., Belhadj O., et al. A novel extended-spectrum TEM-type β-lactamase (TEM-138) From Salmonella enterica serovar Infantis. Antimicrob Agents Chemother 50 9 (2006) 3183-3185
11. Bonnet R., De Champs C., Sirot D., Chanal C., Labia R., and Sirot J. Diversity of TEM mutants in Proteus mirabilis. Antimicrob Agents Chemother 43 (1999) 2671-2677
12. Luzzaro F., Perilli M., Amicosante G., Lombardi G., Belloni R., Alessanro Z., et al. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of β-lactam/β -lactamase inhibitor combinations. Int J Antimicrob Agents 17 (2001) 131-135
13. Nagano N., Shibata N., Saitou Y., Nagano Y., and Arakawa Y. Nosocomial outbreak of infections by Proteus mirabilis that produces extend-spectrum CTX-M-2 Type β-lactamase. J Clin Microbiol 41 (2003) 5530-5536
14. Ben Achour N., Chouchani C., and Belhadj O. increasing resistance to ceftriaxone in clinical strain of Klepsiella pneumoniae. Microbiologie et hygiène alimentaire 18 (2006) 20-26
15. Cavallo JD, Chardon H, Chidiac C, Choutet P, Courvalin P, Dabernat H and et al. Comité de l'antibiogramme de la société française de microbiologie communiqué 2006.
16. Perret C.J. Iodometric assey of penicillinases. Nature 154 (1954) 1012-1013
17. Philippon L., Nass T., Bouthors A.T., Barakett V., and Nordmann P. OXA-18, a class D acid-inhibited extended spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 41 (1997) 2188-2195
18. Ross G.W., and O'Callaghan C.H. In: Hash H. (Ed). β-lactamases assays. Methods in enzymology (1975), Academic Press, New York (XIIII:69-85)
19. Réjiba S., Limam F., Belhadj C., Belhadj O., and Ben-Mahrez K. Biochemical characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Microb Drug Resist 8 (2002) 9-13
20. Hanahan, D. (1985). Technique for transformation of E.coli. DNA cloning (ed. D.M. Glover). 1: 109-135.
21. Bush K., Jacoby G.A., and Medeiros A.A. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39 (1995) 1211-1233
22. Canton R., and Mcoque T. The CTX β-lactamase pandemic. Curr Opin Microbiol 9 (2006) 466-475